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The development of cardiac dysfunction caused by microbial infection predicts high
mortality in sepsis patients. Specialized pro-resolving mediators (SPMs) mediate
resolution of inflammation in many inflammatory diseases, and are differentially expressed
in plasma of sepsis patients. Here, we investigated whether the levels of SPMs
are altered in the murine septic heart following polymicrobial sepsis-induced cardiac
dysfunction. Ten weeks-old male C57BL/6 mice were subjected to polymicrobial sepsis
induced by cecal ligation and puncture (CLP), which is a clinically relevant sepsis model
receiving analgesics, antibiotics, and fluid resuscitation. CLP caused a significant systolic
dysfunction assessed by echocardiography. The hearts were subjected to LC-MS/MS
based lipid mediator profiling. Many SPMs were significantly reduced in septic hearts,
among which RvE1 had a ∼93-fold reduction. Treatment of CLP mice with synthetic
RvE1 (1 µg/mouse i.v.) at 1 h after CLP increased peritoneal macrophages number,
particularly MHC II− macrophages. RvE1 reduced pro-inflammatory gene expression
(interleukin-1β, interleukin-6, and CCL2) in lipopolysaccharide-stimulated bone marrow-
derived macrophages (BMDMs) in vitro. RvE1 attenuated cardiac dysfunction in septic
mice and increased cardiac phosphorylated Akt; decreased cardiac phosphorylated IκB
kinase α/β, nuclear translocation of the NF-κB subunit p65, extracellular signal–regulated
kinase 1/2, and c-Jun amino-terminal kinases 1/2. Most notably, RvE1 treatment
reduced peritoneal bacterial load and promoted phagocytosis activity of BMDMs.
In conclusion, cardiac SPMs, particularly RvE1, are substantially reduced in mice
with polymicrobial sepsis. Delayed therapeutic administration of RvE1 to mice with
polymicrobial sepsis attenuates the cardiac dysfunction through modulating immuno-
inflammatory responses. In addition to the above effects, the ability to enhance
bacterial clearance makes RvE1 an ideal therapeutic to reduce the sequalae of
polymicrobial sepsis.
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INTRODUCTION
Sepsis is a lethal syndrome caused by a systemic dysregulation of
host response to a bacterial, viral or fungal infection (1). About
50% of patients with sepsis develop cardiac dysfunction (2). The
presence of cardiac dysfunction causes the mortality rate in septic
patients to increase by 40–70% (3). The development of cardiac
dysfunction in septic patients is associated with increased levels
of pro-inflammatory cytokines, however, treatment targeting
pro-inflammatory mediators in sepsis patients has had limited
success (4). Moreover, the previously reported benefit of “early
goal-directed therapy” providing cardiovascular support to
patients with sepsis (5) has not been reproduced in multicenter
clinical trials (6). Thus, novel pharmacological strategies
which reduce sepsis-induced cardiac (organ) dysfunction, while
enhancing bacterial clearance are urgently needed.
Resolution of inflammation is a physiological, active
programme to terminate inflammation and enable homeostasis,
coordinated by a number of endogenous specialized pro-
resolving mediators (SPMs), including resolvins (Rvs),
protectins, maresins (MaRs), and lipoxins (LXs) (7). Recently,
we have reported that patients with sepsis showed differentially
expressed SPMs; this was correlated with survival and acute
respiratory distress syndrome development (8).
Rvs, including E-series (RvE) and D-series resolvins, are
derived from ω-3 polyunsaturated fatty acids eicosapentaenoic
acid (EPA) and docosahexaenoic acid, respectively (9). In
particular, RvE1 is biosynthesized from EPA via either aspirin-
acetylated cyclooxygenase-2 (COX-2) or cytochrome P450
monooxygenase in combination with 5-lipoxygenase (10).
RvE1 potently promotes the resolution of inflammation in
many animal models of inflammatory diseases, such as
periodontal disease (11), allergic airway inflammation (12),
and bacterial pneumonia (13). However, the role of RvE1
or other SPMs in the polymicrobial sepsis-induced cardiac
dysfunction is unknown. Thus, the aim of the present
study is to analyze the levels of SPMs in the heart tissue
in mice with sepsis. Having found that septic challenge
leads to substantial reductions of multiple SPMs, particularly
RvE1 (∼93-fold), we have then investigated the potential
beneficial effects of the delayed therapeutic administration
of synthetic RvE1 in a clinically relevant polymicrobial




The local “Animal Use and Care Committee” approved animal
experiments in accordance with the derivatives of both, the
“Home Office guidance on the Operation of Animals (Scientific
Procedures) Act 1986,” and the “Guide for the Care and Use
of Laboratory Animals” of the National Research Council. This
study was carried out on 49 ten weeks-old male C57BL/6
mice (Charles River, Kent, UK), receiving a standard diet and
water ad-libitum.
Model of Polymicrobial Sepsis Caused by
Cecal Ligation and Puncture (CLP) and
RvE1 Treatment
CLP surgery was conducted in mice as described previously
(14, 15). Based on previous evidence and preliminary data,
an 18-G needle was used with the double puncture technique
in order to generate reproducible cardiac dysfunction during
the early phase of sepsis (24 h). Briefly, anesthesia was
induced with 3% isoflurane and maintained at 2% for the
duration of the surgery. Buprenorphine (0.05 mg/kg i.p.) was
injected additionally to provide adequate analgesia. The rectal
temperature of the animals was maintained at 37◦C with a
homeothermic blanket. The abdomen was opened via a 1.5 cm
midline incision, and the cecum exposed. The cecum was
ligated just below the ileocecal valve and punctured at both
opposite ends. After a small amount of fecal matter was
extruded from both ends, the cecum was placed back in its
anatomical position and the abdomen was sutured. Ringer’s
solution was given s.c. for resuscitation directly after surgery
(1 ml/mouse) and 6 h and 18 h after surgery (0.5 ml/mouse).
Antibiotic (Imipenem/Cilastin; 20 mg/kg s.c.) and analgesia
(buprenorphine; 0.05 mg/kg i.p.) was administered 6 and
18 h after surgery. Sham-operated mice were not subjected to
ligation or perforation of cecum but were otherwise treated
the same way. One hour after CLP or sham-operation, mice
were treated either with RvE1 (1 µg/mouse i.v.; CAS number
552830-51-0; Cayman Chemical) (16) or vehicle (100 µl PBS,
0.1% Ethanol). A clinical score for monitoring the health of
experimental mice was used to evaluate the symptoms consistent
with murine sepsis. The maximum score of 6 comprised the
presence of the following signs: lethargy, piloerection, tremors,
periorbital exudates, respiratory distress, and diarrhea. Mice
with a clinical score >3 were defined as exhibiting severe
sepsis, against a moderate sepsis for a score ≤3. At 24 h
after surgical procedures, cardiac function was assessed by
echocardiography in vivo. Mice were then deeply anesthetized
with 3% isoflurane, blood was taken by cardiac puncture, and
mice were euthanized with CO2. Heart samples were stored
at−80◦C for further analysis.
To generate heart samples for lipid mediator qualification,
mice were randomly allocated into two different groups: (i)
Sham-operation (n= 5); (ii) CLP (n= 7).
In RvE1 therapeutic study for cardiac function analysis, mice
were randomly allocated into four different groups: (i) Sham-
operation + Vehicle (n = 6); (ii) Sham-operation + RvE1 (1
µg/mouse, n = 6); (iii) CLP + Vehicle (n = 8); (iv) CLP + RvE1
(1 µg/mouse, n= 8).
Assessment of Cardiac Function in vivo
Cardiac function was assessed in mice by echocardiography
in vivo as reported previously (14, 17). At 24 h after CLP,
anesthesia was induced with 3% isoflurane and maintained at
0.5–0.7% for the duration of the procedure. Before assessment
of cardiac function, mice were allowed to stabilize for at least
10min. During echocardiography the heart rate was obtained
from electrocardiogram (ECG) tracing and the temperature
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was monitored with a rectal thermometer. Two-dimensional
and M-mode echocardiography images were recorded using
a Vevo-770 imaging system (VisualSonics, Toronto, Ontario,
Canada). Percentage fractional area change (FAC) was assessed
from a two-dimensional trace and percentage ejection fraction
(EF) and percentage fractional shortening (FS) were calculated
from the M-mode measurements in the parasternal short
axis view at the level of the papillary muscles. Calculation
of percentage EF and FS requires the measurements of left
ventricle internal dimension (LVID) in diastolic and systolic
phase from M-mode, and calculation of FAC requires the
measurements of LV end-systolic and end-diastolic areas from
the B-mode.
Lipid Mediator Qualification
After cardiac function analysis, mice were then deeply
anesthetized with 3% isoflurane, and were euthanized with
CO2. Hearts were placed in ice cold MeOH containing
deuterated internal standards (d4-LTB4, d8-5S-HETE, d4-
PGE2, d5-LXA4, and d5-RvD2, 500 pg each). These were
gently homogenized, kept at −20◦C for 45min to allow for
protein precipitation the subjected to solid phase extraction
(18). Methyl formate fractions were brought to dryness using
a TurboVap LP (Biotage) and products suspended in water-
methanol (50:50 vol:vol) for LC-MS/MS. Here a Shimadzu
LC-20AD HPLC and a Shimadzu SIL-20AC autoinjector
(Shimadzu, Kyoto, Japan), paired with a QTrap 5500 (ABSciex,
Warrington, UK) was utilized and operated as described
previously (18). To monitor each LM and respective pathways,
an MRM method was developed with diagnostic ion fragments
(Table S1) and identification using recently published criteria
(18), including matching retention time (RT) to synthetic
and authentic materials and at least six diagnostic ions for
each LM. Calibration curves were obtained for each using
authentic compound mixtures and deuterium labeled LM at
3.12, 6.25, 12.5, 25, 50, 100, and 200 pg. Linear calibration
curves were obtained for each LM, which gave r2 values
of 0.98–0.99.
Western Blot Analysis
Mice were euthanized with CO2 as described above. Semi-
quantitative western blot analysis was carried out in mouse heart
tissues as described previously (19, 20).
Briefly, mouse heart samples were homogenized in 10%
homogenization buffer and centrifuged at 1,300 × g for
5min at 4◦C. Supernatants were removed and centrifuged
at 16,000 × g at 4◦C for 40min to obtain supernatant
containing the cytosolic fraction. The pelleted nuclei were re-
suspended in extraction buffer (1/3 volume of the homogenation
buffer) containing 20mM HEPES (pH 7.9), 1.5mM MgCl2,
420mM NaCl, 0.2mM EDTA, 20% glycerol, 1mM EGTA
(and inhibitor of protease) and incubated in ice for 30min,
followed by centrifugation at 16,000 g for 20min at 4◦C.
The resulting supernatants containing nuclear proteins were
carefully removed, and protein content was determined on both
nuclear and cytosolic extracts using a bicinchoninic acid (BCA)
protein assay following the manufacturer’s directions (Therma
Fisher Scientific, Rockford, IL). Proteins were separated by
8% sodium dodecyl sulphatepolyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to a polyvinyldenedifluoride
(PVDF) membrane, which were blocked with a solution of
5% dry milk in TBS-Tween for 2 h. Membranes were the
incubated, overnight, with a primary antibody: rabbit anti-
total inhibitor of kappa B kinase (IKK) α/β; rabbit anti-
phospho-IKKα/β Ser176/180; rabbit anti-NF-κB p65; rabbit anti-
total Akt; mouse anti-phospho-Akt pSer473; rabbit anti-total
p44/42 MAPK (Erk1/2); rabbit anti-phospho-p44/42 MAPK
(Erk1/2) (Thr202/Tyr204); rabbit anti-total-SAPK/JNK, mouse
anti-phospho-SAPK/JNK (Thr183/Tyr185) were used at 1:1000
dilution. Blots were then incubated with a secondary antibody
conjugated with horseradish peroxidase (dilution 1:10000) for
30min at room temperature and developed with the ECL
detection system. The immunoreactive bands were visualized
by autoradiography. Densitometric analysis of the bands was
performed using the Bio-Rad Image Lab TM 6.0.1 Software.
Each group was then adjusted against corresponding sham data
to establish relative protein expression when compared with
sham animals.
Bacteria Counting
The mice were euthanized with CO2 at 24 h after the CLP. The
skin of the abdomen was cut open after disinfection and without
damage to the muscle layer, the peritoneal cavity was washed
with 4mL of sterile PBS with 2mM EDTA. Aliquots of serial
log dilutions of the obtained peritoneal lavage were plated on LB
Broth with agar plates, colony-forming units (CFU) were counted
after incubation in humidified incubator at 37◦C for 24 h, the
results were expressed as the number of CFU per ml.
Flow Cytometry
Mice were euthanized with CO2 as described above. Peritoneal
exudate was taken from four CLP + Vehicle and five CLP
+ RvE1 mice. Peritoneal cells were differentiated using anti-
CD11b (clone M1/70; eBioscience), anti-F4/80 (clone BM8;
BioLegend), anti-Ly6G (clone 1A8; BioLegend), anti-I-A/I-
E (clone M5/114.15.2; BioLegend), anti-Ly6C (clone HK1.4;
BioLegend), anti-CD64 (clone X54-5/7.1; BioLegend) antibodies.
Zombie NIRTM Fixable Viability Kit (Biolegend) was used
to identify live cells. Cell counts were determined using
Precision Count Beads (Biolegend). Ten thousand live cell
events were acquired with a FACSCalibur (Becton Dickinson)




Bone marrow derived macrophages were generated as previously
described (21). Briefly, Male C57BL/6J mice were euthanized
with CO2. Tibiae and femurs from these mice were flushed
with PBS and bone marrow cells were re-suspended in
Dulbecco Modified Eagle’s Medium supplemented with 10%
heat-inactivated FBS, 10% L929-conditioned medium (which
is a source of M-CSF) and 1% Penicillin-Streptomycin. Cells
were cultured for seven days at 37◦C/5% CO2 and on
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day 3 media was changed (only adherent cells were left
in culture).
IncuCyte Zoom Phagocytosis
BMDMs treated with either vehicle or 10 nM RvE1 for 30min
were then incubated with unopsonized pHrodo Green E. coli
Bioparticles (ThermoFisher Scientific, Loughborough, UK) at
0.1 mg/ml in a 96-well flat clear bottom plate. The plate was
then placed into the IncuCyte Zoom platform (Essen Bioscience,
Welwyn Garden City, UK) which was housed inside a humidified
incubator at 37◦C, 5% CO2. Two to four images per well
from three technical replicates were taken every 20min for
5 h using a 20× objective lens and then analyzed using the
IncuCyteTM Basic Software. Green channel acquisition time was
400 ms.
mRNA Expression Analysis
BMDMs were pre-treated with 10 nM RvE1 for 30min followed
by 2 h lipopolysaccharide (LPS) (0.1µg/ml) stimulation. BMDMs
mRNA was extracted with TRIzol reagent (Thermo Fisher
Scientific), and total RNA concentration and quality were
determined with a ND-1000 spectrophotometer (Nano Drop
Technologies, Wilmington, DE, USA). cDNA was synthesized
from 1,000 ng RNA using the QuantiTect Reverse Transcription
kit (Qiagen, Manchester, UK) according to the manufacturer’s
instructions. Real-time quantitative PCR was performed using
either Taqman or Sybr Select gene expression master mix
(Life Technologies) in the StepOnePlusTM thermal cycler
(Applied Biosystems). Primers were purchased from Qiagen
(tnfα, il-6, ccl2, il-1b, and 18S). Cycle threshold values
were determined by the StepOne software and target gene
expression was normalized to housekeeping gene (βactin).
Relative expression results were plotted as mRNA expression
divided by 18S expression.
Statistics
All values described in the text and figures are presented as
mean ± standard error of the mean (SEM) of n observations,
where n represents the number of animals studied. Statistical
analysis was performed using GraphPad Prism 7.0 (GraphPad
Software, San Diego, California, USA). One-way ANOVA
followed by Bonferroni’s post-hoc test or unpaired Student’s
t-test were used to compare intergroup differences. Comparing
results were considered statistically significant when P < 0.05.
Partial Least Square Discriminant Analysis were performed
using MetaboAnalyst (22). Here, features with a constant
or single value across samples were deleted. Partial Least
Square Discriminant Analysis was then performed following
auto-scaling (mean-centered and divided by the standard
deviation of each variable). PLS-DA is based on a linear
multivariate model that identifies variables that contribute
to class separation of observations on the basis of their
variables (LM levels). During classification, observations
were projected onto their respective class model. The
score plot illustrates the systematic clusters among the
observations (closer plots presenting higher similarity in
the data matrix).
Materials
All materials, reagents, and solutions were purchased from
Sigma Aldrich (Poole, Dorset, UK), unless otherwise stated.
Antibodies for immunoblot analysis were purchased from Cell
Signaling Antibodies.
RESULTS
SPMs, Particularly RvE1, Levels Were
Substantially Reduced in Hearts From Mice
With Polymicrobial Sepsis
CLP-induced polymicrobial sepsis caused significant cardiac
dysfunction indicated by reductions in percentage EF, FS and
FAC (P < 0.05; Figures 1A–D). To investigate whether this
polymicrobial sepsis-induced cardiac dysfunction was associated
with changes in pro-resolving mediators, hearts were harvested
from mice following CLP or sham surgery. The profiles of
pro-resolving mediators for the eicosapentaenoic acid and
docosahexaenoic acid bioactive metabolomes in the mouse heart
were determined by LC-MS/MS based lipid mediator profiling.
We identified mediators from all four pro-resolving mediator
families including resolvins, protectins, and maresins (Table S1),
in accordance with published criteria (18). Principle component
analysis of total lipid mediators demonstrated a marked shift in
lipid mediator profiles in cardiac tissue from CLP mice when
compared with tissues obtained from sham mice (Figure 1E).
This shift was linked with a significant reduction in levels of
multiple pro-resolving mediators including RvE1, 17R -RvD1,
17R -RvD3, MaR1, RvT2, RvT3, RvD1n−3DPA, RvD2n−3DPA,
and LXB4, etc (Figures 1F–M, Table S1), among which the
levels of RvE1 were the most reduced (sham: 251.9 ± 104.3
vs. CLP: 2.7 ± 1.0 pg/heart; ∼93-fold reduction; P < 0.05).
These findings led us to postulate that reductions in the cardiac
levels of SPMs, particularly RvE1, may play a pivotal role in
the pathophysiology of the cardiac dysfunction in mice with
polymicrobial sepsis.
RvE1 Treatment Attenuated Cardiac
Dysfunction and Improved Clinical
Outcome in Mice With Polymicrobial
Sepsis
Having found that RvE1 was substantially reduced in the heart
following polymicrobial sepsis challenge, we investigated if
treatment with synthetic RvE1 attenuated polymicrobial sepsis-
induced cardiac dysfunction.When compared with sham surgery
plus vehicle mice, sham surgery mice treated with RvE1 showed
no significant alterations in percentage EF, FS, and FAC (P >
0.05; Figures 2A–D). When compared with sham surgery mice,
mice underwent CLP surgery plus vehicle developed significant
cardiac dysfunction indicated by significant reductions in
percentage EF, FS, and FAC (P < 0.05; Figures 2A–D); they
were significantly attenuated by delayed administration of RvE1
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1 h after CLP (P < 0.05; Figures 2A–D). Additionally, when
compared with CLP mice with vehicle administration, RvE1
treatment significantly improved clinical scores in CLP mice:
At 24 h post-CLP, 75% CLP mice with vehicle administration
recorded a score >3, indicating severe sepsis, whereas 100% of
RvE1-treated CLP mice developed moderate sepsis (score, ≤3)
(Figure 2E).
RvE1 Treatment Improved the Host
Immune Response to Polymicrobial Sepsis
Analysis of peritoneal exudates by flow cytometry (Figure 3A)
showed a trend for increased (although not significant)
peritoneal myeloid cells at 24 h post-CLP in RvE1-treated CLP
mice compared to CLP mice with vehicle administration (CLP
+ vehicle: 2.79 ± 1.80 (×106) vs. CLP + RvE1: 6.16 ± 0.66
(×106); P = 0.09), this increase was mainly due to increased
Ly6G−CD64+ monocytes/macrophages recruitment (P <
0.05; Figures 3B,C). No significant difference was observed
in Ly6G+CD64− neutrophils (P > 0.05; Figures 3B,D).
Ly6G−CD64+ monocytes/macrophages were subclassified
as CD64lowLy6Chigh monocytes and CD64highLy6Clow
macrophages (23), the later subset was further subclassified
as major histocompatibility complex (MHC) II+ and MHC
II− macrophages (23). When compared to mice that had
CLP surgery plus vehicle, mice which underwent CLP surgery
and were treated with RvE1 had significantly increased
CD64highLy6Clow macrophages within the peritoneum (P <
0.05; Figures 3E,F), this was mainly attributed to the increase
in MHC II− macrophages (P < 0.05; Figures 3H,I), while no
significant change was observed in MHC II+ macrophages (P >
0.05; Figures 3H,J) or CD64lowLy6Chigh monocytes (P > 0.05;
Figures 3E,G).
RvE1 Reduced mRNA Expression of
Pro-inflammatory Proteins in BMDMs With
LPS Stimulation in vitro
BMDMs stimulated with LPS (0.1µg/ml) for 2 h resulted in
significant increases in mRNA expression of pro-inflammatory
cytokines and chemokines including IL-6, IL-1β, TNFα, and
CCL2 (P < 0.05; Figures 4A–D). Pre-treatment with 10 nM
RvE1 prior to LPS stimulation significantly attenuated the
increases in IL-6, IL-1β, and CCL2 mRNA expression (P < 0.05;
Figures 4A–C). There was a trend that TNFα mRNA expression
was also reduced with RvE1 treatment compared with vehicle
control (P = 0.09; Figure 4D).
RvE1 Treatment Attenuated Changes in
Cardiac Akt Phosphorylation, Activation of
Nf-κB, and ERK1/2 and JNK1/2
Phosphorylation in Mice With
Polymicrobial Sepsis
To gain a better mechanistic insight into the cardioprotective
effects of RvE1 in mice with polymicrobial sepsis, we
investigated the effects of RvE1 treatment on the cardiac
phosphorylation of Akt on Ser473, phosphorylation of IKKα/β
on Ser176/180, subsequent nuclear translocation of p65 NF-
κB, and phosphorylation of ERK1/2 on Tyr202 and Tyr204
and JNK1/2 on Thr183 and Thr185. RvE1 administration did
not alter any of the above parameters in sham surgery mice
(Figures 5A–E). When compared to sham surgery mice, CLP
surgery mice given vehicle exhibited a significantly lower
degree of cardiac phosphorylation of Akt on Ser473. In contrast,
RvE1 treatment to CLP surgery mice significantly attenuated
the decrease in cardiac phosphorylation of Akt on Ser473
(P < 0.05; Figure 5A).
When compared to sham surgery mice, CLP surgery
mice given vehicle exhibited significantly increased cardiac
phosphorylation of IKKα/β on Ser176/180, nuclear translocation
of p65 NF-κB phosphorylation of ERK1/2 on Tyr202 and
Tyr204 and JNK1/2 on Thr183 and Thr185. In contrast RvE1
treatment to CLP surgery mice significantly attenuated the
increases in IKKα/β phosphorylation, nuclear translocation of
p65, and phosphorylation of ERK1/2 and JNK1/2 (P < 0.05;
Figures 5B–E).
RvE1 Treatment Improved Bacterial
Clearance in vivo and in vitro
Uncontrolled bacterial load contributes to a worse outcome in
sepsis (14), therefore improving bacterial clearance is of utmost
importance for the treatment of sepsis. We therefore investigated
whether RvE1 treatment could alter the bacterial clearance
in mice with polymicrobial sepsis. When compared to CLP
surgery mice given vehicle, RvE1-treated mice exhibited lower
peritoneal bacterial load following CLP surgery as quantified
by colony counts (P < 0.05; Figures 6A,B). As macrophages
were one of the most abundant cell types present in the
inflammatory exudates of mice post-CLP (Figure 3), we further
investigated whether the phagocytic ability of BMDMs was
improved following RvE1 treatment. We performed a pHrodo-
conjugated E. coli phagocytosis assay using the IncuCyte ZOOM
real-time cell imaging system as described previously (24). By
taking images of the green fluorescence emitted by bacteria once
inside the phagolysosome. BMDMs were pre-treated with 10 nM
RvE1 30min prior to the addition of E. coli bioparticles. RvE1
treatment greatly enhanced phagocytosis in BMDMs compared
with vehicle treatment as reflected by the kinetics of phagocytosis
(Figures 6C,D). Plotting the area under the curve of the kinetics
traces (up to 5 h) illustrated that BMDMs treated with RvE1 had
significantly increased green object counts compared with the
control BMDM treated with vehicle (P < 0.05, Figure 6E). These
data suggest that RvE1 enhances BMDMs phagocytosis of E.
coli in vitro. Enhanced phagocytic ability of macrophages might
contribute to the improved bacterial clearance in the peritoneal
cavity of mice with polymicrobial sepsis treated with RvE1.
DISCUSSION
Sepsis is characterized by life-threatening organ dysfunction
caused by a dysregulated host response to microbial infection.
The presence of cardiac dysfunction in patients with sepsis has
been linked to highmorbidity andmortality rates, which together
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FIGURE 1 | CLP causes significant cardiac dysfunction, and leads to a shift in heart tissue lipid mediator profiles and a downregulation of SPMs. (A–D) Cardiac
function was assessed at 24 h after sham or CLP surgery. (A) Representative M–mode echocardiograms and percentages of (B) ejection fraction (C) fractional
shortening, and (D) fractional area change. (E–M) Mice were subjected to CLP or sham surgery and heart tissues were collected after 24 h. Tissues were then
homogenized and mediators were identified and quantified using LC-MS/MS based lipid mediator profiling. (E) Lipid mediator concentrations between the two groups
were then interrogated using Partial Least Square Discriminant Analysis. Score Plot, with each dot representing profiles from each mouse. Cumulative levels for select
SPMs including (F) RvE1, (G) 17R -RvD1, (H) 17R -RvD3, (I) MaR1, (J) RvT2, (K) RvT3, (L) RvD1n−3DPA, and (M) RvD2n−3DPA in mouse hearts subjected to sham or
CLP surgery. Results are expressed in pg/heart. (B,C,F–M) Data are represented as means ± SEM and were analyzed by unpaired Student’s t-test. **P < 0.01, ***P <
0.001, ****P < 0.0001 vs. Sham-operated group. The following groups were studied: Sham-operated (n = 5) and CLP (n = 7). Rv, resolvin; MaR, maresin; LX, lipoxin.
with the associated high socioeconomic costs (1) highlights an
unmet need for identifying novel therapeutic strategies that
attenuate sepsis-induced cardiac dysfunction. We report here for
the first time that the cardiac dysfunction observed in septic mice
is associated with significant reductions in several SPMs in the
heart of septic mice. Particularly the levels of the pro-resolution
mediator RvE1 were reduced by ∼93-fold in the heart. As RvE1
is a potent pro-resolving mediator, which has clinical efficacy
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FIGURE 2 | One hour post-treatment of RvE1 attenuates CLP-induced cardiac dysfunction and sepsis-associated clinical scores in mice. Mice underwent sham or
CLP surgery. One hour after CLP, mice were treated with either RvE1 (1 µg/mouse i.v.) or vehicle (100 µl PBS, 0.1% Ethanol). Cardiac function was assessed at 24 h.
(A) Representative M–mode echocardiograms and percentages of (B) ejection fraction (C) fractional shortening, and (D) fractional area change. The following groups
were studied: Sham + Vehicle (n = 6); Sham + RvE1 (n = 6); CLP + Vehicle (n = 8) and CLP + RvE1 (n = 8). All data are represented as means ± SEM. Data were
analyzed by one-way ANOVA followed by Bonferroni post-hoc test. ***P < 0.001 vs. CLP + Vehicle group. (E) At 24 h post-CLP, mice were scored for the presence or
absence of six different macroscopic signs of sepsis, namely, lethargy, piloerection, tremors, periorbital exudates, respiratory distress, and diarrhea. A clinical score >3
is considered as severe sepsis. Data are from 16 mice and were analyzed by unpaired Student’s t-test. **P < 0.01 vs. CLP + Vehicle group.
in humans with dry eye-associated inflammation (25) and has
therapeutic effects in rodent models of myocardial infarction (26,
27) and LPS-induced cardiac injury (28), we hypothesized that
reductions in endogenous levels of SPMs, particularly RvE1, may
contribute to development of cardiac dysfunction in sepsis. To
investigate this hypothesis, we have added back synthetic RvE1
to mice with polymicrobial sepsis-induced cardiac dysfunction.
We report here for the first time that delayed treatment of
RvE1 using a therapeutic approach (i.e., 1 h after CLP surgery)
significantly attenuates the cardiac dysfunction and promotes
bacterial clearance in polymicrobial sepsis (Figure 7).
We also observed an increased macrophages number,
particularly MHC II− macrophage subset in the peritoneum
of septic mice treated with RvE1. MHC II− macrophages
express more M2-associated genes such as CD36, CD163,
Mertk, and Arg1. While MHC II+ macrophages express
more M1-associated genes such as CD80, CD86, and Il1b
(23). Classically activated M1-like macrophages express pro-
inflammatory cytokines (TNFa, IL-1β, and IL-6) and is involved
in the initiation and maintenance of inflammation, whereas
the alternatively activated M2-like macrophages express anti-
inflammatory cytokines (IL-10, TGF-β) which drive resolution
of inflammation, wound healing, and tissue repair (29).
Interestingly, while we see an increase in macrophage number
in mice treated with RvE1 following CLP surgery they do
not appear to be MHC II+ macrophages, which have a
pro-inflammatory phenotype, suggesting RvE1 treatment is
reducing macrophage pro-inflammatory activation. Importantly,
M2 macrophages produce higher levels of SPMs including RvE2,
RvD5, MaR1, and LXA4 compared with M1, but lower levels
of pro-inflammatory prostanoids and leukotrienes (30). Early-
stage sepsis is associated with a hyperinflammatory response
(31). Here we have shown that RvE1 increases macrophages
number in the peritoneum, particularly MHC II− macrophages
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FIGURE 3 | RvE1 treatment enhances MHC II− macrophage recruitment in peritoneal cavity. Mice underwent CLP surgery. One hour after CLP, mice were treated
with either RvE1 (1 µg/mouse i.v.) or vehicle (100 µl PBS, 0.1% Ethanol). (A) Flow cytometry gating strategy of mouse peritoneal immune cells 24 h post-CLP. (B)
Scattergrams illustrating monocyte/macrophage (identified as Ly6G−CD64+) and neutrophil (identified as Ly6G+CD64−) positive events in peritoneal lavages from
CLP mice with vehicle or RvE1 treatment. (C,D) Cumulative data for peritoneal CD64+ monocytes/macrophages and Ly6G+ neutrophils. (E) Scattergrams illustrating
macrophage (identified as CD64highLy6Clow) and monocyte (identified as CD64lowLy6Chigh) positive events in peritoneal lavages from CLP mice with vehicle or RvE1
treatment. (F,G) Cumulative data for peritoneal CD64highLy6Clow macrophages and CD64lowLy6Chigh monocytes. (H) Scattergrams illustrating MHC II− macrophage
and MHC II+ macrophage positive events in peritoneal lavages from CLP mice with vehicle or RvE1 treatment. (I,J) Cumulative data for peritoneal MHC II−
macrophages and MHC II+ macrophages. Data are expressed as mean ± SEM of four mice for vehicle group and five mice for RvE1 treatment group. Data were
analyzed by unpaired Student’s t-test. *P < 0.05 vs. CLP + Vehicle group.
suggesting that RvE1 treatment may induce a phenotypic switch
in macrophages. This may drive M2-like pro-resolving effects
in mice with polymicrobial sepsis, suggesting that RvE1 has
the therapeutic potential for sepsis through the modulation of
macrophages inflammation. It should be noted that the later anti-
inflammatory stage of sepsis is the result of a self-regulatory
mechanism in response to severe systemic inflammation.
Therefore, enhancement pro-resolving effects in macrophage by
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FIGURE 4 | RvE1 reduces pro-inflammatory mRNA expression in BMDMs with LPS stimulation in vitro. BMDMs were treated with 10 nM RvE1 or vehicle after 2 h LPS
(0.1µg/ml) stimulation. Real-time quantitative PCR of (A) IL-6, (B) IL-1β, (C) CCL2, and (D) TNFα expression, relative to 18S rRNA. Each analysis (A–D) is from a
single experiment and is representative of six separate experiments. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. LPS + Vehicle
group. US, unstimulated.
RvE1 at the early stages of polymicrobial sepsis may prevent later
immune suppression.
In line with our in vivo observations, we have shown
reduced formation of pro-inflammatory cytokines, IL-6 and
IL-1β, and chemokine, CCL2, transcripts in LPS-stimulated
BMDMs following RvE1 pre-treatment in vitro. The secretion of
pro-inflammatory cytokines by macrophages is a key driver in
the pathophysiology of the cardiac dysfunction in sepsis, as these
cytokines decrease the myofibril response to calcium, enhance
mitochondrial dysfunction, and downregulate β receptors (1).
Akt is a member of a conserved family of phosphoinositide 3-
kinases (PI3K) signal transduction enzymes; activation of which
mediates cell survival and growth, and has cardioprotective
effects (20, 32). Here we demonstrate that RvE1 treatment
preserves Akt-phosphorylation and, hence, activity in the heart
of mice with sepsis. Indeed, activation of the pro-survival Akt
pathway has been reported to reduce sepsis-induced cardiac
dysfunction (15, 33, 34). Our previous studies have shown that
activation of Akt results in inhibition of the activation of NF-
κB which was associated with attenuated cardiac dysfunction
(35) and reduction of acute kidney injury (36) in murine sepsis.
Mechanically, the pro-resolving effects of RvE1 are transduced
through ChemR23 receptor (37). Indeed, RvE1 regulates Akt
phosphorylation through ChemR23, for instance, in human
ChemR23-transfected Chinese hamster ovary cells (38). Notably,
RvE1 augments Akt activity in the border zone of hearts
exposed to ischemia-reperfusion which is associated with a
reduced infarct size (26). RvE1 also activates Akt in cardiac
cells (H9c2 cardiac embryonic myoblast line) exposed to hypoxia
or hypoxia/reoxygenation (26). Thus, we speculate that the
activation of Akt induced by RvE1 in the heart contributes to the
improvement in cardiac dysfunction caused by sepsis.
NF-κB is one of the most potent pro-inflammatory
transcription factors, which consists of heterodimer-subunits
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FIGURE 5 | RvE1 improves cardiac phosphorylation of Akt and attenuates the increases in cardiac phosphorylation of IKKα/β, nuclear translocation of p65, ERK1/2,
and JNK1/2 in CLP mice. Mice underwent sham or CLP surgery. One hour after CLP, mice were treated with either RvE1 (1 µg/mouse i.v.) or vehicle (100 µl PBS,
0.1% Ethanol). Signaling events in heart tissue were assessed at 24 h. Densitometric analysis of the bands is expressed as relative optical density (O.D.) of (A)
phosphorylated Akt (pSer473) corrected for the corresponding total Akt content and normalized using the related sham band; (B) phosphorylated IKKα/β (pSer176/180)
(Continued)
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FIGURE 5 | corrected for the corresponding total IKKα/β content and normalized using the related sham band; (C) NF-κB p65 subunit levels in both, cytosolic and
nuclear fractions expressed as a nucleus/cytosol ratio normalized using the related sham bands; (D) ERK1/2 phosphorylation, corrected for the corresponding total
ERK1/2 content and normalized using the related sham band; (E) JNK1/2 phosphorylation, corrected for the corresponding total JNK1/2 content and normalized
using the related sham band. Each analysis (A–E) is from a single experiment and is representative of three to four separate experiments. Data are expressed as mean
± SEM for n number of observations. Data were analyzed by one-way ANOVA followed by Bonferroni’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. CLP +
Vehicle group.
FIGURE 6 | RvE1 treatment improves peritoneal bacterial clearance in mice with CLP, and promotes phagocytosis activity in BMDMs in vitro. (A,B) Mice underwent
CLP surgery. One hour after CLP, mice were treated with either RvE1 (1 µg/mouse i.v.) or vehicle (100 µl PBS, 0.1% Ethanol). (A) Representative images of
colony-forming units (CFU) and (B) Measurement of bacteria levels in peritoneal lavages 24 h post-CLP from mice with vehicle or RvE1 treatment. Data are expressed
as mean ± SEM of six mice for vehicle group and five mice for RvE1 treatment group. Data were analyzed by unpaired Student’s t-test. *P < 0.05 vs. CLP + Vehicle
group. (C–E) BMDMs were pre-treated with RvE1 (10 nM) for 30min, and then incubated with pH-rodo Green E. coli bioparticles (0.1 mg/ml), and fluorescence
emission was measured in the IncuCyte imaging platform every 20min for 5 h at 37◦C. (C) Representative images from the IncuCyte software from one of n = 4
separate experiments are shown. Scale bar 200µm. (D) The kinetics of phagocytosis at 20min intervals. (E) Quantification of data in (D) showing area under the
curve for 5 h following pH-rodo Green E. coli bioparticles addition. Data are presented as mean ± SEM from four biological replicates in technical duplicates. Data
were analyzed by unpaired Student’s t-test. **P < 0.01 vs. Vehicle group.
p50 and p65 (39). We have demonstrated that RvE1 treatment
in mice with polymicrobial sepsis is associated with a robust
reduction in IKK α/β phosphorylation and, thus, nuclear
translocation of p65 in the heart. These findings are in line
with our previous studies which show that activation of
NF-κB pathway plays a key role in the pathophysiology of
sepsis-induced cardiac dysfunction and that inhibition of
NF-κB activation attenuates the cardiac function in sepsis
(15). RvE1 has been shown to suppress NF-κB activation in
pulmonary macrophages in vitro (40). The suppression of
NF-κB activation in macrophages may have contributed to
our observed reduced pro-inflammatory protein transcripts in
RvE1-treated BMDMs. Additionally, NF-κB activation can be
induced by the exposure to proinflammatory cytokines, such
as IL-1β and TNFα (41). Therefore, reduced pro-inflammatory
cytokines leads to decreased NF-κB activation, thus further
dampens the inflammatory reaction, which contributes to
attenuated polymicrobial sepsis-induced cardiac dysfunction.
Moreover, the observed reduction in ERK1/2 and JNK1/2
phosphorylation upon RvE1 treatment may lead to less
NF-κB activation and decreased cytokine production, thus
generate a positive feedback loop and further reduce the
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FIGURE 7 | Schematic summary: RvE1 attenuates polymicrobial sepsis-induced cardiac dysfunction and enhances bacterial clearance. The upper panel displays
substantial reduction of multiple SPMs, particularly RvE1, in the heart of mice with polymicrobial sepsis, and this reduction was associated with the development of
profound cardiac dysfunction. The lower panel shows delayed therapeutic administration of RvE1 attenuated polymicrobial sepsis-induced cardiac dysfunction and
augmented bacterial clearance, and its associated mechanisms as demonstrated in vivo and in vitro.
inflammation in the heart (42). Mechanically, it has been
shown that RvE1 inhibits TNFα-induced NF-κB activation
via ChemR23 in HEK293 cells transfected with ChemR23
receptor (37).
SPMs such as RvD1, RvD5, and PD1 enhance phagocytosis
and lower antibiotic requirements for bacterial clearance (43).
Indeed, in this study, RvE1 treatment leads to improved
bacterial clearance in the peritoneal cavity (measured as
reduction in bacterial counts). We propose that an increased
bacterial clearance by RvE1 will limit inflammation and
improve resolution in septic mice. In line with our study,
another resolvin, RvD2, has been shown to improve survival
rate of septic mice by limiting the number of live aerobic
bacteria in both blood and peritoneum (44). Additionally,
RvE1 protects mice from bacterial pneumonia and acute
lung injury by enhancing clearance of E. coli (13). In
our study, we have observed an increase in macrophage
recruitment in the peritoneal cavity after RvE1 treatment which
may have contributed to the improved bacterial clearance.
Indeed, our in vitro study has shown that addition of RvE1
augmented phagocytosis of E. coli in BMDMs. Mechanically,
RvE1 enhances phagocytosis in human monocyte-derived
macrophages in a ChemR23-dependent manner (38). Similarly,
in mice, RvE1 enhances peritoneal macrophage phagocytosis,
and these effects are absent in peritoneal macrophages obtained
from ChemR23 knockout mice (45). Particularly, ChemR23
is upregulated in human M1 macrophages, and such M1
macrophages show increased phagocytosis in response to RvE1
stimulation, whereas humanM2macrophages do not express the
receptor (46).
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Interestingly, a recent study has shown that pre-treatment of
RvE1 inhibits the infiltration of macrophages into the heart and
spleen in mice with LPS-induced cardiac injury (28), whereas
our study show that RvE1 increases macrophages number in the
peritoneal cavity where live bacteria are released. Zhang et al.’s
results compliment the data in the present study; macrophages
have an important role in the clearance of bacteria, they
recognize bacteria via pattern recognition receptors (PRRs),
which is essential for macrophage activation, phagocytosis, and
bacteria killing by the host (47). Here we have shown RvE1
increases macrophages number in peritoneum associated with an
enhanced bacterial clearance, which is of utmost importance in
improving the clinical outcome of mice with sepsis. However, it
is possible that RvE1 acts differently onmacrophages recruitment
to loci such as heart and spleen where no bacterium is present,
by reducing macrophages infiltration to limit pro-inflammatory
responses and preserve organ functions; this merits future
investigation. Over-activation of PRRs may cause systemic
inflammatory response and elicit harmful damage to the host
(47). In our study, although we have seen an increased number of
macrophages upon RvE1 treatment, the majority of macrophages
are non-pro-inflammatory MHC II− macrophages, indicating
that while promoting the phagocytotic activity, RvE1 also reduces
pro-inflammatory activation of macrophages. In line with our
study, RvD2 treatment also increases peritoneal mononuclear
cells in CLP-induced peritonitis, which contributes to a reduced
bacterial burden in peritoneal cavity (44).
LIMITATIONS OF THE STUDY
We have shown that RvE1 treatment leads to greater cardiac
phosphorylation of Akt and reduced activation of cardiac NF-
κB, ERK1/2, and JNK1/2 phosphorylation, which is associated
with improved cardiac function. However, this in vivo study does
not allow us to identify specific cell types that are involved in
RvE1-induced beneficial changes in cardiac signaling pathways.
The pro-resolving effects of RvE1 act through ChemR23 receptor
(37) which expresses in macrophages and neutrophils (48).
Indeed, our in vitro study has shown that RvE1 dampens
the inflammatory reaction of BMDMs in response to LPS
stimulation. Clearly, cardiomyocytes are the most predominant
cell type in the heart, impaired cardiomyocyte contractility
directly leads to cardiac dysfunction. Reduced pro-inflammatory
cytokines secreted by immune cells upon RvE1 treatment may
have improved cardiomyocyte contractility. However, what is
more intriguing is that ChemR23 is expressed in murine
cardiomyocytes, this reinforces possible direct effects of RvE1 in
activation of cardiomyocytic ChemR23 receptor however, further
work is needed to confirm this (49).
CONCLUSIONS
This paper shows for the first time that the development
of cardiac dysfunction induced by a clinically relevant
polymicrobial sepsis model is associated with low levels of SPMs,
particularly RvE1 (∼93-fold reduction), in the heart. This finding
formed the basis for our hypothesis that restoration of RvE1 in
polymicrobial sepsis may reduce the cardiac dysfunction. Indeed,
therapeutic administration of RvE1 1 h after CLP surgery reduced
cardiac dysfunction and improved clinical performance in mice
with polymicrobial sepsis receiving analgesics, antibiotics, and
fluid resuscitation. RvE1 also aids resolution by increasing
MHC II− macrophage recruitment to the peritoneum. More
importantly, we have shown that RvE1 treatment enhances
phagocytosis of macrophages resulting in a reduced peritoneal
bacterial load in mice with sepsis, which is of utmost importance
in the therapy of sepsis. We propose that the beneficial effects
of RvE1 on septic hearts are secondary to the modulated host
immune response, greater cardiac phosphorylation of Akt, and
reductions in the activation of cardiac NF-κB, ERK1/2, and
JNK1/2. Thus, RvE1 may represent a novel pro-resolving and
anti-inflammatory therapeutic approach for the treatment of
cardiac dysfunction and assisting bacterial clearance in sepsis.
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